CREPT在肾癌组织中的表达及其与预后的关系

doi:10.3969/j.issn.1006-7795.2020.04.010

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (4): 552-557.doi: 10.3969/j.issn.1006-7795.2020.04.010

• 泌尿系统肿瘤基础与临床 • 上一篇下一篇

CREPT在肾癌组织中的表达及其与预后的关系

刘军¹, 曹庆飞², 叶雄俊¹, 陈伟男¹, 赵海岳¹, 佟明², 王银银³, 黄晓波¹, 常智杰³

1. 北京大学人民医院泌尿与碎石中心, 北京 100034;
2. 锦州医科大学附属第一医院泌尿外科, 辽宁锦州 121001;
3. 清华大学医学院膜生物国家重点实验室, 北京 100084

收稿日期:2020-04-27 出版日期:2020-08-21 发布日期:2020-07-22
通讯作者: 叶雄俊 E-mail:yexiongjun@bjmu.edu.cn
基金资助:
北京大学医学科技创新平台发展基金—青年培育基金资助项目（BMU2018PY012）。

Relationship between CREPT expression and prognosis in renal cell carcinoma

Liu Jun¹, Cao Qingfei², Ye Xiongjun¹, Chen Weinan¹, Zhao Haiyue¹, Tong Ming², Wang Yinyin³, Huang Xiaobo¹, Chang Zhijie³

1. Urology and Lithotripsy Center, Peking University People's Hospital, Beijing 100034, China;
2. Department of Urinary Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, Liaoning Province, China;
3. State Key Laboratory Membrane Biology, School of Medicine, Tsinghua University, Beijing 100084, China

Received:2020-04-27 Online:2020-08-21 Published:2020-07-22
Supported by:
This study was supported by Fund for Fostering Young Scholars of Peking University Health Science Center (BMU2018PY012).

摘要/Abstract

摘要： 目的探讨肾癌组织中肿瘤细胞周期相关蛋白（cell-cycle-related and expression-elevated protein in tumor，CREPT）的表达与临床病理特征和生存率的关系。方法纳入90例于2014至2016年间在北京大学人民医院接受了根治性肾切除术并经组织学证实的肾癌患者，运用免疫组织化学方法检测这些患者的癌组织和癌旁组织中CREPT的表达，并结合临床病理资料分析CREPT表达水平与患者TNM分期和Fuhrman分级的关系。通过Kaplan-Meier生存分析及多因素COX回归分析CREPT表达与预后的关系。结果 46.7%（42/90）的患者癌组织中CREPT表达为高水平，而在癌旁组织中所有患者CREPT表达均为低水平，组间比较差异有统计学意义（P<0.05）。CREPT的表达水平与TNM分期（P=0.001）和Fuhrman分级（P<0.001）有关联，但与性别（P=0.149）、年龄（P=0.605）、肿瘤大小（P=0.673）和组织学类型（P=0.756）无关。截至2018年12月，有85例患者完成随访。Kaplan-Meier分析显示，CREPT高表达患者总生存时间和无瘤生存时间均低于CREPT低表达患者，差异有统计学意义（P<0.05）。多因素COX回归分析显示，患者总生存时间及无瘤生存时间与CREPT的表达水平有关（P<0.05）。结论 CREPT在肾癌组织中呈高表达，表达水平与临床分期、分级以及患者预后密切相关。

关键词: 肾细胞癌, 肿瘤细胞周期相关蛋白, 预后

Abstract: Objective To explore the expression levels of cell-cycle-related and expression-elevated protein in tumor (CREPT) in renal cell carcinoma (RCC) and its association with cancer prognosis and patient survival. Methods A total of 90 patients who were diagnosed with RCC from 2014 to 2016 in our hospital were enrolled. Immunohistochemistry (IHC) was applied to assess CREPT expression level in RCC and adjacent normal renal tissue. The clinicopathologic features (TNM stage, Fuhrman grade) and CREPT expression level were analyzed. Furthermore, prognostic significance of CREPT was evaluated with Kaplan-Meier survival analysis. Results The expression of CREPT was high in 46.7% (42/90) of the cancer tissues, but low in all the adjacent normal tissues. The difference between groups was statistically significant (P<0.05). The degree of CREPT expression was significantly associated with TNM stage (P=0.001) and Fuhrman grade (P<0.001). However, no significant relationship between CREPT and gender (P=0.149), age (P=0.605), tumor size (P=0.673) and histological type (P=0.756) were identified. Totally 85 patients had completed follow-up until December 2018. The Kaplan-Meier analysis showed that patients with higher expression level of CREPT had significantly worse overall survival (OS) (P<0.05) and disease-free survival (DFS) (P<0.05). Conclusions CREPT was highly expressed in RCC. The expression level was positively associated with the degree of malignancy, clinical stage, and cancer prognosis.

Key words: renal cell carcinoma, cell-cycle-related and expression-elevated protein in tumor(CREPT), prognosis

中图分类号:

R737.11

刘军, 曹庆飞, 叶雄俊, 陈伟男, 赵海岳, 佟明, 王银银, 黄晓波, 常智杰. CREPT在肾癌组织中的表达及其与预后的关系[J]. 首都医科大学学报, 2020, 41(4): 552-557.

Liu Jun, Cao Qingfei, Ye Xiongjun, Chen Weinan, Zhao Haiyue, Tong Ming, Wang Yinyin, Huang Xiaobo, Chang Zhijie. Relationship between CREPT expression and prognosis in renal cell carcinoma[J]. Journal of Capital Medical University, 2020, 41(4): 552-557.

参考文献 17

[1]	Makhov P, Joshi S, Ghatalia P, et al. Resistance to systemic therapies in clear cell renal cell carcinoma:mechanisms and management strategies[J]. Mol Cancer Ther, 2018,17(7):1355-1364.
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[3]	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju T F, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016:A Systematic Analysis for the Global Burden of Disease Study[J]. JAMA Oncol, 2018,4(11):1553-1568.
[4]	Choueiri T K, Motzer R J. Systemic therapy for metastatic renal-cell carcinoma[J]. N Engl J Med,2017,376(4):354-366.
[5]	Buchler T, Poprach A, Bortlicek Z, et al. Outcomes of patients with long-term treatment response to vascular endothelial growth factor-targeted therapy for metastatic renal cell cancer[J]. Clin Genitourin Cancer, 2017,15(6):e1047-e1053.
[6]	Lu D, Wu Y, Wang Y, et al. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes[J]. Cancer Cell, 2012, 21(1):92-104.
[7]	Sun M, Si G, Sun H S, et al. Inhibition of CREPT restrains gastric cancer growth by regulation of cycle arrest, migration and apoptosis via ROS-regulated p53 pathway[J]. Biochem Biophys Res Commun, 2018,496(4):1183-1190.
[8]	Sinn B V, von Minckwitz G, Denkert C, et al. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer[J]. Ann Oncol, 2013,24(9):2316-2324.
[9]	Kim J K, Diehl J A. Nuclear cyclin D1:an oncogenic driver in human cancer[J]. J Cell Physiol, 2009, 220(2):292-296.
[10]	Massagué J. G1 cell-cycle control and cancer[J]. Nature, 2004, 432(7015):298-306.
[11]	Karim S, Al-Maghrabi J A, Farsi H M, et al. Cyclin D1 as a therapeutic target of renal cell carcinoma-a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia[J]. BMC Cancer, 2016,16(Suppl 2):741.
[12]	黄子成,陈清,翁晓源,等.Pin1与CyclinD1在胃肠间质瘤中的表达及临床意义[J].中国医科大学学报,2017,46(6):495-500.
[13]	Mei K R, Jin Z, Ren F L, et al. Structural basis for the recognition of RNA polymerase II C-terminal domain by CREPT and p15RS[J]. Sci China Life Sci, 2014, 57(1):97-106.
[14]	Zhang Y, Wang S, Kang W, et al. CREPT facilitates colorectal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation[J]. Oncogene, 2018,37(26):3485-3500.
[15]	Li W, Zheng G, Xia J, et al. Cell cycle-related and expression-elevated protein in tumor overexpression is associated with proliferation behaviors and poor prognosis in non-small-cell lung cancer[J]. Cancer Sci, 2018,109(4):1012-1023.
[16]	She Y, Liang J, Chen L, et al. CREPT expression correlates with poor prognosis in patients with retroperitoneal leiomyosarcoma[J]. Int J Clin Exp Pathol,2014,7(10):6596-6605.
[17]	Zhang Y, Liu C, Duan X, et al. CREPT/RPRD1B, a recently identified novel protein highly expressed in tumors, enhances the β-catenin·TCF4 transcriptional activity in response to Wnt signaling[J]. J Biol Chem,2014,289(33):22589-22599.

CREPT在肾癌组织中的表达及其与预后的关系

Relationship between CREPT expression and prognosis in renal cell carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 17

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王荣荣, 田俊萍. 急性冠脉综合征患者血清钙与心血管预后的关系[J]. 首都医科大学学报, 2023, 44(1): 154-160.
[2]	贾静, 陈文明, 李燕郴. 多发性骨髓瘤伴中枢侵犯临床特征及预后分析[J]. 首都医科大学学报, 2023, 44(1): 161-166.
[3]	于天宇, 姜世敏, 高红梅, 邹古明, 李文歌. 糖尿病肾病慢性肾脏病4期患者肾脏临床及病理因素与预后的关系[J]. 首都医科大学学报, 2022, 43(5): 707-712.
[4]	郭康林, 程一春, 葛树旺, 徐钢. IgA肾病国际风险预测工具在中国人群中的预测效果评价[J]. 首都医科大学学报, 2022, 43(5): 713-719.
[5]	谷强, 余孝君, 张津. 高龄与中低龄老年轻型缺血性脑卒中临床特点及预后分析[J]. 首都医科大学学报, 2022, 43(3): 474-479.
[6]	周巧云, 黄晓武, 夏恩兰, 赵玉婷, 黄睿. 子宫动脉栓塞后宫腔粘连的生殖结局分析[J]. 首都医科大学学报, 2022, 43(3): 490-494.
[7]	苗祖霈, 张迎花, 肖克令, 司瑾, 张浩宇, 李静. 肥胖程度对急性ST段抬高型心肌梗死患者预后的影响[J]. 首都医科大学学报, 2022, 43(2): 192-198.
[8]	孙婧, 史幼梧, 贾军, 杨颖, 孙志伟, 杜丰, 余靖, 肖艳洁, 张晓东. 血液炎症相关指标在晚期胰腺癌中的预后价值[J]. 首都医科大学学报, 2022, 43(2): 299-304.
[9]	刘洋, 吴玉梅, 何玥, 樊蓓, 王雁, 赵辉, 王明. ⅠB期子宫颈癌国际妇产科联盟2018新分期的合理性验证及评估[J]. 首都医科大学学报, 2021, 42(6): 1026-1032.
[10]	王莉, 张国军. 血清神经元特异性烯醇化酶与外伤性脑损伤患者及临床特征的关系[J]. 首都医科大学学报, 2021, 42(5): 715-720.
[11]	来璇, 张爱华. 代谢综合征对慢性肾脏病患者生存预后的影响[J]. 首都医科大学学报, 2021, 42(4): 609-614.
[12]	王欣, 张俊璇, 高健, 石汉平. 免疫营养改善肿瘤患者预后[J]. 首都医科大学学报, 2020, 41(6): 1019-1024.
[13]	吴西抗, 王跃, 贺慧颖. 上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系[J]. 首都医科大学学报, 2020, 41(3): 354-359.
[14]	曹迪, 李先亮, 张荟, 贺强. 影响肝门部胆管癌术后远期预后的因素[J]. 首都医科大学学报, 2020, 41(3): 439-443.
[15]	盛海燕, 刘晓芳, 金建敏, 胥杰, 刘涌. 肺结节病外周血嗜酸性粒细胞增多意义的临床观察[J]. 首都医科大学学报, 2020, 41(3): 475-481.